Clinical Research Of Hydrochloric Donepezil Treatment Of Mild Cognitive Barriers

Objective: Alzheimer’s disease（AD）occurs in old age andearly old, central nervous system degenerative diseases characterized byprogressive cognitive impairment and behavioral damage is the mostcommon type of Alzheimer. AD Has become the fourth leading cause ofdeath of the elderly. Past the point of view, mild cognitive impairment(MCI) is a transitional stage between normal aging and dementia, acognitive dysfunction syndrome. On October11,2010,"LancetNeurology" published online on the AD amend the definition of an expertgroup submissions pointed out that AD is not limited to a dementiasyndrome, but the mild cognitive impairment, including the differentstages of the disease, the clinical process of change, including preclinicalAD、MCI due to AD and AD dementia. Early intervention and treatmentcan significantly reduce the hazards of AD in MCI, thereby reducing theburden on society and the family. Intervention on the treatment of MCIand MCI to dementia of the development is still at the exploratory stage.Inhibitor of acetylcholinesterase is one of the first-line drugs used for ADtreatment currently. donepezil (trade name: Aricept) is the most widelyused AChEI in the world. This study aimed to evaluate the efficacy of thedonepezil in patients with mild cognitive dysfunction, and explore tointervene in an effective way to prevent its conversion to dementia in MCI. Method: October2010to June2011Sichuan Provincial People’sHospital, Department of Neurology, outpatient and inpatient departmentpatients have memory impairment in the elderly population aged60andabove for screening, which MCI according to Petersen is equal to1999todevelop diagnostic criteria patients to make a clinical diagnosis.44casesof MCI patients enrolled were randomly divided into two groups,donepezil group (26cases), vitamin E group (18cases), two groups of24weeks of continuous medication, both maintained the previous basis ofdrugs. the Mini Mental Status Examination, Montreal CognitiveAssessment and Adult Wechsler Memory Scale were assessed before andafter treatment in general cognitive function and memory function,changes in MMSE score, MoCA score and memory quotient in the twogroups were compared before and after treatment. Result:(1) before andafter treatment donepezil group, the memory quotient, the MMSE score,total score of MoCA and sub-delayed memory, attention and visuospatialand executive function score improved significantly;(2) before and aftertreatment vitamin E group, the memory quotient, the MMSE score,MoCA score and sub-score improved significantly;(3) donepezil groupafter treatment, memory quotient, the MMSE score, total score of MoCAand sub-delayed memory, attention and visuospatial and executivefunction scores significantly improved compared with the vitamin Egroup;(4) the course of treatment, two cases of patients with mild dizziness, nausea, loss of appetite, disappeared three days after thewithdrawal, these symptoms did not arise again to continue medication.Conclution:(1) MCI patients in a row to take donepezil for24weeksafter the overall cognitive function and memory function improvedsignificantly;(2) MCI patients in the continuous taking vitamin E for24weeks after the overall cognitive function and memory function improvedsignificantly;(3) Course of treatment, only two cases of patients takingdonepezil, adverse reactions and does not affect the continued medication,the drug has good security.